"Armored" immune cells take on tough blood cancers in early trial
NCT ID NCT03085173
First seen Apr 08, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This early-phase study tests the safety of a special type of immune cell, called an "armored" CAR T-cell, in people with certain blood cancers (like CLL) that have not responded to standard treatments. The cells are made from the patient's own blood and are designed to better attack cancer cells. The main goal is to find a safe dose and see how the body responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.